Zynerba pharmaceuticals, inc. (ZYNE)

CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Cash flows from operating activities:
Net loss

-36,134

-32,943

-30,018

-35,879

-36,751

-39,911

-40,239

-40,743

-37,059

-32,012

0

0

0

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

145

133

124

113

102

99

99

98

100

94

90

91

82

75

66

48

38

26

0

0

0

Stock-based compensation

5,388

5,561

5,952

6,160

6,435

6,625

6,407

6,545

6,145

5,646

5,154

4,236

3,694

3,269

0

0

0

-

-

-

-

Changes in operating assets and liabilities:
Incentive and tax receivables

9,390

11,169

10,351

-1,150

-1,075

-538

-522

-409

154

369

1,336

4,735

4,299

3,257

0

0

0

-

-

-

-

Prepaid expenses and other assets

-1,106

-1,561

-772

-1,291

13

1,291

426

411

207

324

959

311

643

285

1,472

1,080

481

359

0

0

0

Right-of-use assets

2

5

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred grant revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-56

-255

-271

-278

0

0

0

Accounts payable

-815

209

-182

-2,539

-658

1,103

459

4,291

3,593

1,492

1,510

-710

7

1,044

-65

1,651

-273

536

0

0

0

Accrued expenses

3,404

1,833

319

1,051

-910

1,271

936

10

-972

-369

1,597

3,382

4,013

2,011

2,722

1,449

1,512

1,597

0

0

0

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Net cash used in operating activities

-36,296

-34,817

-33,560

-29,488

-31,555

-32,397

-32,903

-29,798

-28,554

-25,842

0

0

0

-

-

-

-

-9,786

0

0

0

Cash flows from investing activities:
Purchases of property and equipment

242

129

210

193

293

286

181

154

64

115

113

159

149

109

126

198

238

216

0

0

0

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Net cash used in investing activities

-242

-129

-210

-193

-293

-286

-181

-154

-64

-115

0

0

0

-

-

-

-

-216

0

0

0

Cash flows from financing activities:
Proceeds from the issuance of common stock

28,290

45,187

0

0

0

-

-

-

-

57,293

0

0

0

-

-

-

-

-

-

-

-

Payment of financing fees and expenses

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Net cash provided by financing activities

28,879

45,246

0

0

0

-

-

-

-

57,502

0

0

0

-

-

-

-

42,185

0

0

0

Net (decrease) increase in cash and cash equivalents

-7,660

10,299

11,370

45,546

16,167

-2,746

-73

-27,064

-25,361

31,544

0

0

0

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

32,182

0

0

0

Supplemental disclosures of cash flow information:
Deferred financing costs included in accounts payable and accrued expenses

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Property and equipment acquired unpaid at end of period

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in property and equipment acquired but not paid

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Reclassification of deferred rent liability to right-of-use assets upon adoption of ASC 842

-

12

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Right-of-use assets and lease liability recorded upon adoption of ASC 842

-

325

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred offering costs included in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0